An­ti­bod­ies once act­ed on­ly as pro­tein block­ers. Now, sci­en­tists are find­ing new ways to make them pro­tein de­stroy­ers

8 months ago
Discovery

The End­points 11: The top pri­vate biotechs in pur­suit of new drugs. Push­ing the en­ve­lope with pow­er­ful new tech­nolo­gies

8 months ago
Special

Lab coats and mi­cro­scopes in mar­ket­ing: Does sci­ence still sell in phar­ma ad­ver­tis­ing?

8 months ago
Pharma
Marketing

#ES­MO22: Round­table dis­cus­sion with John Car­roll

8 months ago

Backed by five phar­ma gi­ants and a crew of Penn su­per­stars, a start­up us­es mR­NA to cre­ate in vi­vo CAR-T — with a pro at the helm

8 months ago
Financing
Startups

#ES­MO22: Am­gen drops the de­tailed deck for KRAS G12C, with erod­ing da­ta like­ly to trig­ger fresh de­bate

8 months ago
R&D

#ES­MO22: 'End of the be­gin­ning': As PD-(L)1s press on, how far can com­bo ther­a­pies take im­muno-on­col­o­gy?

8 months ago
R&D
Pharma

#ES­MO22: Am­gen spot­lights con­fir­ma­to­ry win for KRAS G12C play­er Lumakras in lung can­cer — but there's plen­ty more da­ta to come

8 months ago
R&D

Noth­ing to laugh about: What hap­pened to hu­mor in phar­ma ad­ver­tis­ing?

8 months ago
Pharma
Marketing

Phar­ma's day in court: Is the dai­ly down­pour of law­suits giv­ing phar­ma com­pa­nies a bad rep?

9 months ago
Pharma
Marketing

Chi­na's DNA gi­ant con­fronts skep­ti­cism in US ex­pan­sion bid

9 months ago
China
In Focus

Af­ter years of fail­ures, the hunt for a new type of Parkin­son’s drug is on

9 months ago
R&D
In Focus

Q&A: GSK vac­cine leader Judy Stew­art nav­i­gates vac­ci­na­tion slumps, al­ways-on mar­ket­ing and in­no­vat­ing da­ta tools

9 months ago
Pharma
Marketing

Biotech's 'sug­ar high' led to a cor­rec­tion, but win­ter dol­drums could make way for a turn­around sto­ry this fall

9 months ago
Financing
In Focus

Biotech’s down­turn fu­els a bil­lion­aire’s niche in­vest­ment in­dus­try

9 months ago
R&D
In Focus

ICY­MI: James Sabry just signed off on a land­mark first for Roche's deal­mak­ing crew

9 months ago
Bioregnum
China

Those big bil­lion-dol­lar PhI­II stud­ies? Mar­tin Lan­dray says they can be done for a tiny frac­tion of the cost

9 months ago
R&D
In Focus

Cerev­el's Tony Coles is still count­ing his mon­ey as a ri­val's boost helps fu­el a po­ten­tial $609M wind­fall

9 months ago
Financing
Bioregnum

CEO of Doud­na spin­out: With­in five years, genome ed­i­tors will have a 're­al­ly big im­pact' on pa­tients' lives

9 months ago
Cell/Gene Tx

'Messy at best': Is the US re­peat­ing the same Covid mis­steps with mon­key­pox mes­sag­ing?

9 months ago
Pharma
Marketing

Why non-opi­oid pain drugs keep fail­ing — and what's next for the field

9 months ago
R&D
In Focus

Q&A: Astel­las' re­tir­ing head of de­vel­op­ment re­flects on gene ther­a­py deaths

9 months ago
People
Cell/Gene Tx

George Yan­copou­los says he's on the trail of the holy grail: ‘This could rep­re­sent the next break­through for im­munother­a­py’

10 months ago
Bioregnum
Pharma

Gran­flu­encers and boom­flu­encers: Is the hip­ster old­ster so­cial me­dia trend mov­ing to phar­ma?

10 months ago
Pharma
Marketing
First page Previous page 6789101112 Next page Last page
A service from the Financial Times